Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04750330
Other study ID # COVIDmtDNA1.0
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date June 12, 2023

Study information

Verified date June 2023
Source Maastricht University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In December 2019, the first people got infected with COVID-19 in Wuhan, China. Within weeks, this highly infectious disease spread all over the world. Nearly one year later everyone is still trying to battle this disease and facing the consequences it causes. What became clear is that the disease and its severity differs largely between infected people. However, knowledge about who will experience severe COVID-19 and who does not is still unclear. Therefore, the aim of this study is to investigate the prognostic value of certain parameters (mtDNA and CT radiomics signature) for the severity of COVID-19.


Description:

In December 2019, the first cases of coronavirus disease 2019 (COVID-19) were diagnosed in Wuhan, China. Within a couple of weeks, the highly contagious disease spread across the world, requiring rapid and drastic measures, unparalleled in recent decades. Currently, there have been approximately 97.8 million cases, including 2.1 million deaths, reported to the WHO (website accessed January 25th, 2021, https://covid19.who.int). Data from published epidemiology and virologic studies show that the virus is mainly passed on by respiratory droplets, by direct contact with infected people, or by contact with contaminated objects and surfaces. The severity of the disease greatly differs between people. It ranges from non-symptomatic contamination or minor symptoms, such as a cold or sore throat, to life-threatening pneumonia and death. Especially, the elderly population and people with underlying comorbidities are vulnerable and experience more severe symptoms. In addition, studies have shown that males have a higher mortality risk. COVID-19 is currently diagnosed using reverse-transcription polymerase chain reaction (RT-PCR). In the beginning of the pandemic the use of chest computed tomography (CT) was more common, since CT can capture imaging features from the lung associated with COVID-19 early in the course of the disease. However, performing a CT-can takes remarkably longer than current RT-PCR tests. While the epidemic continues, the consequences are slowly becoming more apparent. As the true population infection rate is unknown, the proportion of patients requiring hospital admission is difficult to estimate. In a meta-analysis including 1481 unique publications a pooled rate of ICU admission of 10.9% and the pooled rate of mortality was 4.3%. The negative effects of an ICU stay strongly depend on the length of the stay and include, but are not limited to, risk of lung emboly, severe muscle loss, dysphagia and psychological problems, often necessitating a long period of rehabilitation. To minimize long-term health consequences early prognosis of the severity of the disease would be beneficial. The link between the severity of COVID-19 and mitochondrial DNA (mtDNA), Nuclear SNPs, imaging features and radiomics has not been studied yet. However, literature about mechanistic insights in the functioning of the immune system and its link to genetic variation, including mtDNA, are promising. In addition, studies focusing on imaging features and radiomics have yielded interesting findings.


Recruitment information / eligibility

Status Completed
Enrollment 394
Est. completion date June 12, 2023
Est. primary completion date June 12, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Confirmed COVID-19 disease - Age at least 18 years - Willing and able to provide a saliva sample - Able to understand the patient study information - Signed informed consent Exclusion Criteria: Exclusion criteria for hospitalized patients - Severe illness other than COVID-19 at hospital admission Exclusion criteria for non-hospitalized patients - Severe COVID-19 illness leading to death or requiring active treatment without hospital admission

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Greece Regional Chest Diseases Hospital of Athens <Sotiria> Athens
Italy University of Florence Firenze
Portugal Centro Hospitalar de Setúbal Setúbal

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University Innovative Medicines Initiative

Countries where clinical trial is conducted

Greece,  Italy,  Portugal, 

References & Publications (41)

Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20. doi: 10.1002/0471142905.hg0720s76. — View Citation

Ardakani AA, Kanafi AR, Acharya UR, Khadem N, Mohammadi A. Application of deep learning technique to manage COVID-19 in routine clinical practice using CT images: Results of 10 convolutional neural networks. Comput Biol Med. 2020 Jun;121:103795. doi: 10.1016/j.compbiomed.2020.103795. Epub 2020 Apr 30. — View Citation

Benetti E, Tita R, Spiga O, Ciolfi A, Birolo G, Bruselles A, Doddato G, Giliberti A, Marconi C, Musacchia F, Pippucci T, Torella A, Trezza A, Valentino F, Baldassarri M, Brusco A, Asselta R, Bruttini M, Furini S, Seri M, Nigro V, Matullo G, Tartaglia M, Mari F; GEN-COVID Multicenter Study; Renieri A, Pinto AM. ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. Eur J Hum Genet. 2020 Nov;28(11):1602-1614. doi: 10.1038/s41431-020-0691-z. Epub 2020 Jul 17. — View Citation

Bhopal SS, Bhopal R. Sex differential in COVID-19 mortality varies markedly by age. Lancet. 2020 Aug 22;396(10250):532-533. doi: 10.1016/S0140-6736(20)31748-7. Epub 2020 Aug 13. No abstract available. — View Citation

Breda CNS, Davanzo GG, Basso PJ, Saraiva Camara NO, Moraes-Vieira PMM. Mitochondria as central hub of the immune system. Redox Biol. 2019 Sep;26:101255. doi: 10.1016/j.redox.2019.101255. Epub 2019 Jun 15. — View Citation

Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat. 2009 Aug;30(8):1237-44. doi: 10.1002/humu.21047. — View Citation

Capriotti E, Altman RB, Bromberg Y. Collective judgment predicts disease-associated single nucleotide variants. BMC Genomics. 2013;14 Suppl 3(Suppl 3):S2. doi: 10.1186/1471-2164-14-S3-S2. Epub 2013 May 28. — View Citation

Carter-Timofte ME, Jorgensen SE, Freytag MR, Thomsen MM, Brinck Andersen NS, Al-Mousawi A, Hait AS, Mogensen TH. Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. Front Immunol. 2020 Jun 30;11:1606. doi: 10.3389/fimmu.2020.01606. eCollection 2020. — View Citation

Chocron ES, Munkacsy E, Pickering AM. Cause or casualty: The role of mitochondrial DNA in aging and age-associated disease. Biochim Biophys Acta Mol Basis Dis. 2019 Feb 1;1865(2):285-297. doi: 10.1016/j.bbadis.2018.09.035. Epub 2018 Nov 9. — View Citation

Clohisey S, Baillie JK. Host susceptibility to severe influenza A virus infection. Crit Care. 2019 Sep 5;23(1):303. doi: 10.1186/s13054-019-2566-7. — View Citation

Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix AN, Thys M, Henket M, Canivet G, Mathieu S, Eftaxia E, Lambin P, Tsoutzidis N, Miraglio B, Walsh S, Moutschen M, Louis R, Meunier P, Vos W, Leijenaar RTH, Lovinfosse P. Development and Validation of an Automated Radiomic CT Signature for Detecting COVID-19. Diagnostics (Basel). 2020 Dec 30;11(1):41. doi: 10.3390/diagnostics11010041. — View Citation

Hosey MM, Needham DM. Survivorship after COVID-19 ICU stay. Nat Rev Dis Primers. 2020 Jul 15;6(1):60. doi: 10.1038/s41572-020-0201-1. — View Citation

Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020 Jul 15;18(1):216. doi: 10.1186/s12916-020-01673-z. — View Citation

Jaiswal A, Gianchandani N, Singh D, Kumar V, Kaur M. Classification of the COVID-19 infected patients using DenseNet201 based deep transfer learning. J Biomol Struct Dyn. 2021 Sep;39(15):5682-5689. doi: 10.1080/07391102.2020.1788642. Epub 2020 Jul 3. — View Citation

Kuo CL, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, Melzer D. ApoE e4e4 Genotype and Mortality With COVID-19 in UK Biobank. J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1801-1803. doi: 10.1093/gerona/glaa169. No abstract available. — View Citation

Lai JH, Luo SF, Ho LJ. Operation of mitochondrial machinery in viral infection-induced immune responses. Biochem Pharmacol. 2018 Oct;156:348-356. doi: 10.1016/j.bcp.2018.08.044. Epub 2018 Aug 31. — View Citation

Leonardi A, Scipione R, Alfieri G, Petrillo R, Dolciami M, Ciccarelli F, Perotti S, Cartocci G, Scala A, Imperiale C, Iafrate F, Francone M, Catalano C, Ricci P. Role of computed tomography in predicting critical disease in patients with covid-19 pneumonia: A retrospective study using a semiautomatic quantitative method. Eur J Radiol. 2020 Sep;130:109202. doi: 10.1016/j.ejrad.2020.109202. Epub 2020 Jul 29. — View Citation

Li B, Clohisey SM, Chia BS, Wang B, Cui A, Eisenhaure T, Schweitzer LD, Hoover P, Parkinson NJ, Nachshon A, Smith N, Regan T, Farr D, Gutmann MU, Bukhari SI, Law A, Sangesland M, Gat-Viks I, Digard P, Vasudevan S, Lingwood D, Dockrell DH, Doench JG, Baillie JK, Hacohen N. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection. Nat Commun. 2020 Jan 9;11(1):164. doi: 10.1038/s41467-019-13965-x. — View Citation

Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009 Jul 15;25(14):1754-60. doi: 10.1093/bioinformatics/btp324. Epub 2009 May 18. — View Citation

Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R; 1000 Genome Project Data Processing Subgroup. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009 Aug 15;25(16):2078-9. doi: 10.1093/bioinformatics/btp352. Epub 2009 Jun 8. — View Citation

Li X, Zhou TC, Wu CH, Tao LL, Bi R, Chen LJ, Deng DY, Liu C, Otecko NO, Tang Y, Lai X, Zhang L, Wei J. Correlations between mitochondrial DNA haplogroup D5 and chronic hepatitis B virus infection in Yunnan, China. Sci Rep. 2018 Jan 17;8(1):869. doi: 10.1038/s41598-018-19184-6. — View Citation

Liu F, Zhang Q, Huang C, Shi C, Wang L, Shi N, Fang C, Shan F, Mei X, Shi J, Song F, Yang Z, Ding Z, Su X, Lu H, Zhu T, Zhang Z, Shi L, Shi Y. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020 Apr 27;10(12):5613-5622. doi: 10.7150/thno.45985. eCollection 2020. — View Citation

Malik AN, Parsade CK, Ajaz S, Crosby-Nwaobi R, Gnudi L, Czajka A, Sivaprasad S. Altered circulating mitochondrial DNA and increased inflammation in patients with diabetic retinopathy. Diabetes Res Clin Pract. 2015 Dec;110(3):257-65. doi: 10.1016/j.diabres.2015.10.006. Epub 2015 Oct 22. — View Citation

Mei X, Lee HC, Diao KY, Huang M, Lin B, Liu C, Xie Z, Ma Y, Robson PM, Chung M, Bernheim A, Mani V, Calcagno C, Li K, Li S, Shan H, Lv J, Zhao T, Xia J, Long Q, Steinberger S, Jacobi A, Deyer T, Luksza M, Liu F, Little BP, Fayad ZA, Yang Y. Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. Nat Med. 2020 Aug;26(8):1224-1228. doi: 10.1038/s41591-020-0931-3. Epub 2020 May 19. — View Citation

Ovsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. Immunol Rev. 2020 Jul;296(1):205-219. doi: 10.1111/imr.12897. Epub 2020 Jul 13. — View Citation

Pejaver V, Mooney SD, Radivojac P. Missense variant pathogenicity predictors generalize well across a range of function-specific prediction challenges. Hum Mutat. 2017 Sep;38(9):1092-1108. doi: 10.1002/humu.23258. Epub 2017 Jun 12. — View Citation

Santorsola M, Calabrese C, Girolimetti G, Diroma MA, Gasparre G, Attimonelli M. A multi-parametric workflow for the prioritization of mitochondrial DNA variants of clinical interest. Hum Genet. 2016 Jan;135(1):121-36. doi: 10.1007/s00439-015-1615-9. Epub 2015 Nov 30. — View Citation

Severe Covid-19 GWAS Group; Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, Asselta R, Grimsrud MM, Milani C, Aziz F, Kassens J, May S, Wendorff M, Wienbrandt L, Uellendahl-Werth F, Zheng T, Yi X, de Pablo R, Chercoles AG, Palom A, Garcia-Fernandez AE, Rodriguez-Frias F, Zanella A, Bandera A, Protti A, Aghemo A, Lleo A, Biondi A, Caballero-Garralda A, Gori A, Tanck A, Carreras Nolla A, Latiano A, Fracanzani AL, Peschuck A, Julia A, Pesenti A, Voza A, Jimenez D, Mateos B, Nafria Jimenez B, Quereda C, Paccapelo C, Gassner C, Angelini C, Cea C, Solier A, Pestana D, Muniz-Diaz E, Sandoval E, Paraboschi EM, Navas E, Garcia Sanchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Blasi F, Tellez L, Blanco-Grau A, Hemmrich-Stanisak G, Grasselli G, Costantino G, Cardamone G, Foti G, Aneli S, Kurihara H, ElAbd H, My I, Galvan-Femenia I, Martin J, Erdmann J, Ferrusquia-Acosta J, Garcia-Etxebarria K, Izquierdo-Sanchez L, Bettini LR, Sumoy L, Terranova L, Moreira L, Santoro L, Scudeller L, Mesonero F, Roade L, Ruhlemann MC, Schaefer M, Carrabba M, Riveiro-Barciela M, Figuera Basso ME, Valsecchi MG, Hernandez-Tejero M, Acosta-Herrera M, D'Angio M, Baldini M, Cazzaniga M, Schulzky M, Cecconi M, Wittig M, Ciccarelli M, Rodriguez-Gandia M, Bocciolone M, Miozzo M, Montano N, Braun N, Sacchi N, Martinez N, Ozer O, Palmieri O, Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P, Rodrigues PM, Blandino Ortiz A, de Cid R, Ferrer R, Gualtierotti R, Nieto R, Goerg S, Badalamenti S, Marsal S, Matullo G, Pelusi S, Juzenas S, Aliberti S, Monzani V, Moreno V, Wesse T, Lenz TL, Pumarola T, Rimoldi V, Bosari S, Albrecht W, Peter W, Romero-Gomez M, D'Amato M, Duga S, Banales JM, Hov JR, Folseraas T, Valenti L, Franke A, Karlsen TH. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 2020 Jun 17. — View Citation

Sheehy LM. Considerations for Postacute Rehabilitation for Survivors of COVID-19. JMIR Public Health Surveill. 2020 May 8;6(2):e19462. doi: 10.2196/19462. — View Citation

Siordia JA Jr. Epidemiology and clinical features of COVID-19: A review of current literature. J Clin Virol. 2020 Jun;127:104357. doi: 10.1016/j.jcv.2020.104357. Epub 2020 Apr 10. — View Citation

Sonney S, Leipzig J, Lott MT, Zhang S, Procaccio V, Wallace DC, Sondheimer N. Predicting the pathogenicity of novel variants in mitochondrial tRNA with MitoTIP. PLoS Comput Biol. 2017 Dec 11;13(12):e1005867. doi: 10.1371/journal.pcbi.1005867. eCollection 2017 Dec. — View Citation

Tang Z, Zhao W, Xie X, Zhong Z, Shi F, Ma T, Liu J, Shen D. Severity assessment of COVID-19 using CT image features and laboratory indices. Phys Med Biol. 2021 Jan 26;66(3):035015. doi: 10.1088/1361-6560/abbf9e. — View Citation

Thomas PD, Kejariwal A. Coding single-nucleotide polymorphisms associated with complex vs. Mendelian disease: evolutionary evidence for differences in molecular effects. Proc Natl Acad Sci U S A. 2004 Oct 26;101(43):15398-403. doi: 10.1073/pnas.0404380101. Epub 2004 Oct 18. — View Citation

van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M, Hofste T, Astuti G, Corominas Galbany J, van der Schoot V, van der Hoeven H, Hagmolen Of Ten Have W, Klijn E, van den Meer C, Fiddelaers J, de Mast Q, Bleeker-Rovers CP, Joosten LAB, Yntema HG, Gilissen C, Nelen M, van der Meer JWM, Brunner HG, Netea MG, van de Veerdonk FL, Hoischen A. Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA. 2020 Aug 18;324(7):663-673. doi: 10.1001/jama.2020.13719. — View Citation

Wang S, Zha Y, Li W, Wu Q, Li X, Niu M, Wang M, Qiu X, Li H, Yu H, Gong W, Bai Y, Li L, Zhu Y, Wang L, Tian J. A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis. Eur Respir J. 2020 Aug 6;56(2):2000775. doi: 10.1183/13993003.00775-2020. Print 2020 Aug. — View Citation

West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol. 2011 Jun;11(6):389-402. doi: 10.1038/nri2975. Epub 2011 May 20. — View Citation

Wu IC, Lin CC, Liu CS, Hsu CC, Chen CY, Hsiung CA. Interrelations Between Mitochondrial DNA Copy Number and Inflammation in Older Adults. J Gerontol A Biol Sci Med Sci. 2017 Jul 1;72(7):937-944. doi: 10.1093/gerona/glx033. — View Citation

Wu Q, Wang S, Li L, Wu Q, Qian W, Hu Y, Li L, Zhou X, Ma H, Li H, Wang M, Qiu X, Zha Y, Tian J. Radiomics Analysis of Computed Tomography helps predict poor prognostic outcome in COVID-19. Theranostics. 2020 Jun 5;10(16):7231-7244. doi: 10.7150/thno.46428. eCollection 2020. — View Citation

Yu Z, Li X, Sun H, Wang J, Zhao T, Chen H, Ma Y, Zhu S, Xie Z. Rapid identification of COVID-19 severity in CT scans through classification of deep features. Biomed Eng Online. 2020 Aug 12;19(1):63. doi: 10.1186/s12938-020-00807-x. — View Citation

Zhang AM, Hu QX, Liu FL, Bi R, Yang BQ, Zhang W, Guo H, Logan I, Zheng YT, Yao YG. Mitochondrial DNA Haplogroup A Decreases the Risk of Drug Addiction but Conversely Increases the Risk of HIV-1 Infection in Chinese Addicts. Mol Neurobiol. 2016 Aug;53(6):3873-3881. doi: 10.1007/s12035-015-9323-y. Epub 2015 Jul 11. — View Citation

Zhang K, Liu X, Shen J, Li Z, Sang Y, Wu X, Zha Y, Liang W, Wang C, Wang K, Ye L, Gao M, Zhou Z, Li L, Wang J, Yang Z, Cai H, Xu J, Yang L, Cai W, Xu W, Wu S, Zhang W, Jiang S, Zheng L, Zhang X, Wang L, Lu L, Li J, Yin H, Wang W, Li O, Zhang C, Liang L, Wu T, Deng R, Wei K, Zhou Y, Chen T, Lau JY, Fok M, He J, Lin T, Li W, Wang G. Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography. Cell. 2020 Jun 11;181(6):1423-1433.e11. doi: 10.1016/j.cell.2020.04.045. Epub 2020 May 4. Erratum In: Cell. 2020 Sep 3;182(5):1360. — View Citation

* Note: There are 41 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Mitochondrial DNA for prediction of COVID-19 severity Mitochondrial DNA variants (extracted from the saliva-sample) Baseline up to 2 years after having had COVID-19
Other Nuclear SNPs for prediction of COVID-19 severity Nuclear SNPs, candidate approach (extracted from the saliva-sample) Baseline up to 2 years after having had COVID-19
Other Radiomic features for COVID-19 severity prediction Radiomics from chest CT-scan of COVID-19 infected participants Baseline
Primary COVID-19 Severity Severity of COVID-19 classified as 'Severe', 'Non-severe' and 'Minor' When the patient is discharged from the hospital, up to 2 months
Secondary Overall survival of the hospitalized population Overall survival of the hospitalized population When the patient is discharged from the hospital, up to 2 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3